VIVUS price target lowered to $17 from $20 at Leerink

Leerink lowered its price target for VIVUS citing softer than expected Qsymia Scripts after the company issued an update yesterday. Leerink notes that actual Q3 Qsymia scripts grew 33% quarter over quarter to around108K, but are trending below its and consensus numbers. The firm keeps an Outperform rating on the stock.

View Comments (0)